Oncology & Cancer

New Waldenstrom's drug shows sustained benefit at two years

The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, ...

Health

FDA questions evidence for lower-risk tobacco product

U.S. health regulators have questions about the data submitted by tobacco maker Swedish Match in its bid to become the first company to market a smokeless tobacco product as less harmful than cigarettes.

Medications

FDA to scrutinize unproven alternative remedies (Update)

Federal officials plan to review the safety and evidence behind alternative remedies like Zicam and Cold-Eeze, products that are protected by federal law, but not accepted by mainstream medicine.

Medications

Questions over value of new antibiotics to tackle resistance

In the first installment of a new series, Peter Doshi, Assistant Professor at the University of Maryland School of Pharmacy and Associate Editor at The BMJ, asks why authorities are approving drugs with little evidence they ...

Medications

New hepatitis C drugs will place strain on health care system

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness ...

page 9 from 40